Kite Pharma's newly approved blood cancer treatment, Yescarta, uses gene therapy techniques not to fix disease-causing genes but to turbocharge T cells, immune system soldiers that cancer can often evade.
There has been heightened scrutiny over pharmacy benefit managers' role in drug pricing in recent years. Anthem's creation of its own pharmacy benefit management company could drive change throughout the industry as health plans and PBMs aim to maintain their competitive edge, experts said.
Opioids accounted for 24% of medication malpractice claims, making it the leading cause of such claims from 2012 to 2016.
On Oct. 17 the Senate Health, Education, Labor and Pensions Committee will hear testimony from officials representing big pharma, generic drug manufacturers and pharmacists in an attempt to understand prescription drug costs.
Ohio healthcare providers are turning to acupuncture to treat pain in the midst of the opioid epidemic.
Pharmacy benefit manger Express Scripts will acquire medical benefits management company EviCore Healthcare for $3.6 billion, a move that will allow the company to access that growing market, the company said Tuesday.
California's legislation marks one of the strictest drug-price transparency laws in the country, as states move to shine a spotlight on rapidly rising costs in the hopes of pressuring drugmakers to keep them down.
According to research by a team of health experts from the University of Nottingham in England, being in a positive mood when you get your flu shot can increase its protective effects.
A new theory posits that a disagreement over inoculations fractured the marriage of Founding Father Benjamin Franklin.
The natural disaster in Puerto Rico has knocked out the manufacturing capacity for small volumes of sodium chloride and dextrose at one of two major suppliers. That could send a ripple effect throughout the U.S. healthcare industry.
Not-for-profit and public hospitals are being forced to cut back on capital expenditures due to rising drug prices and potential cuts to the 340B drug discount program, according to a new survey.
The Food and Drug Administration is opening a new front in its efforts to reduce high drug prices by encouraging development of generic versions of hard-to-make medicines.